An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi
A phase 3 trial of Luspatercept in myeloproliferative neoplasms, run by Celgene, active and no longer recruiting.
Overview
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions is a phase 3 interventional study registered as NCT04717414 by Celgene, with 313 participants enrolled, started 2021-02-25 and due to reach its primary completion in 2025-05-26. Interventions recorded: ACE-536, Placebo. Conditions listed: Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Shares Luspatercept, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Bristol Myers Squibb.
- TrialA Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Bristol Myers Squibb.
- TreatmentFedratinib
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Bristol Myers Squibb.
- Key paperCOMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions
Shares Luspatercept, Bristol Myers Squibb.
- TechnologyTransfusion support and anaemia management
Shares Luspatercept, Myeloproliferative neoplasms (PV, ET, myelofibrosis).